Shockwave Medical launched its new M5+ peripheral intravascular lithotripsy (IVL) catheter at ACC.22, the annual meeting of the American College of Cardiology. According to Shockwave, the solution cuts procedure times by 50% when treating heavily calcified arteries.
This video shows a real-time demonstration of the catheter's ability to bust calcium faster.
The Shockwave M5+ IVL catheter received both CE mark and U.S. Food and Drug Administration (FDA) clearance. It is specifically designed to decrease IVL treatment time, provide alternative access options and expand IVL therapy to patients with larger vessel sizes. It comes in a longer length of 135 centimeters to allow vascular access from the radial arteries. The larger 8 millimeter balloon size also allows use in larger peripheral vessels.
“Shockwave’s new peripheral catheter offers remarkable improvements that enable efficient and effective treatment for some of our most difficult-to-treat patients, some of whom previously could not have been treated with IVL,” said Peter Soukas, MD, of Miriam and Rhode Island Hospitals in Providence, Rhode Island, and one of the first physicians to use the new catheter. “While treating patients with long, severely calcified lesions will always be challenging, the new Shockwave catheter is appropriately sized for larger vessels and has been optimized to expand options for facilitating vessel access, all while decreasing the amount of time needed to perform IVL in the procedure.”
Shockwave M5+ incorporated customer feedback to improve IVL efficiency in tackling complex calcified lesions, including quicker cycle time that delivers two pulses per second. The catheter is specifically designed to treat otherwise difficult-to-treat calcified lesions in the peripheral arterial system of the lower extremities, including the iliac, femoral, ilio-femoral, popliteal, infra-popliteal and renal arteries.
Related Content on Intravascular Lithotripsy to Break Up Calcified Lesions:
Shockwave’s IVL technology gains FDA approval for treating advanced coronary artery disease
Multicenter trial to evaluate IVL treatment for peripheral lesions below the knee
Better Together? An Integrated Market for Calcium-modification Strategies
IVL Turns Standard Balloon Technology into a Powerful Calcium-disruption Tool
Dave Fornell has covered healthcare for more than 17 years, with a focus in cardiology and radiology. Fornell is a 5-time winner of a Jesse H. Neal Award, the most prestigious editorial honors in the field of specialized journalism. The wins included best technical content, best use of social media and best COVID-19 coverage. Fornell was also a three-time Neal finalist for best range of work by a single author. He produces more than 100 editorial videos each year, most of them interviews with key opinion leaders in medicine. He also writes technical articles, covers key trends, conducts video hospital site visits, and is very involved with social media. E-mail: dfornell@innovatehealthcare.com